Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyProspective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients with Advanced RCC: Data from the Phase III JAVELIN Renal 101 Trial

Both immune checkpoint inhibitors (ICIs) and VEGF receptor inhibitors are approved for advanced renal cell carcinoma (RCC) treatment and can cause cardiovascular events (CVs). This randomized study of avelumab plus axitinib vs. sunitinib used prospective monitoring of LVEF and serum cardiac biomarkers to assess for the development of major adverse CV events. The results indicate patients with high baseline troponin T levels and who receive combination ICI and VEGF receptor inhibitor therapy should be monitored closely for adverse cardiac events.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form